[Association between @entity36982 relative copy number and prognosis of @entity14 @entity1 after XXXX -based chemotherapy].

@entity1 @entity901 @entity36982 @entity5 @entity14 @entity694 @entity1349
OBJECTIVE: To investigate the association between receptor-interacting kinase protein 4 ( @entity36982 ) relative copy number (RCN) and prognosis of stage III( @entity14 ( @entity14 ) @entity1 treated with @entity901 -based chemotherapy. METHODS: @entity36982 RCN was determined by real-time PCR and then dichotomized into high @entity36982 RCN group(n=35) and low @entity36982 RCN group (n=104) using the third quartile as the cut-off point. @entity1349 ( @entity1349 ) and @entity1349 ( @entity1349 ) were compared between high and low @entity36982 RCN groups. The subgroup prognostic analysis was also conducted based on @entity5 site. RESULTS: The median follow-up period was 49 months (ranged 4 to 98 months). @entity1 with high @entity36982 RCN had poorer @entity1349 than those with low @entity36982 RCN, which reached marginal significance(median @entity1349 , 43.0 months vs. 53.5 months, P=0.074). Meanwhile there was no significant difference of @entity1349 between two groups (P=0.352). In @entity694 subgroup, high @entity36982 RCN was significantly associated with poor @entity1349 (median @entity1349 , 31.5 months vs. 56.6 months, P=0.015) but not with @entity1349 (P=0.135). In @entity5 subgroup, @entity36982 RCN was not associated with both @entity1349 and @entity1349 (P=0.981, P=0.738). Multivariate analysis revealed that high @entity36982 RCN was an independent prognostic factor of @entity1349 in stage III( @entity14 @entity1 treated with @entity901 -based chemotherapy (HR=2.903, 95% CI: 1.275 to 6.610). CONCLUSION: @entity36982 RCN is significantly associated with @entity1349 in stage III( @entity694 @entity1 receiving @entity901 -based chemotherapy and may be a novel biomarker that can predict the efficacy of @entity901 in @entity694 @entity1 .
